Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck Serono Pens Diagnostics Deal

by Marc S. Reisch
July 22, 2013 | A version of this story appeared in Volume 91, Issue 29

Merck Serono and instrument maker Life Technologies have signed a nonexclusive agreement to develop diagnostic tests to complement Merck’s drugs. The two intend to focus on oncology initially, but they expect to broaden their efforts to cover a range of therapeutic areas. They also plan to work together to win regulatory approval for new drugs and companion diagnostics. Life and Bristol-Myers Squibb reached a similar deal last year. In April, Thermo Fisher Scientific agreed to buy Life for $15.8 billion. Completion of that deal is expected in early 2014.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.